These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 31221150)

  • 1. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
    Li L; Yang L; Cheng S; Fan Z; Shen Z; Xue W; Zheng Y; Li F; Wang D; Zhang K; Lian J; Wang D; Zhu Z; Zhao J; Zhang Y
    Mol Cancer; 2019 Jun; 18(1):108. PubMed ID: 31221150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma.
    Li L; Yang L; Fan Z; Xue W; Shen Z; Yuan Y; Sun X; Wang D; Lian J; Wang L; Zhao J; Zhang Y
    Signal Transduct Target Ther; 2020 May; 5(1):54. PubMed ID: 32439898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1/UBE2T Inhibits CD8
    Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment.
    Cheng CC; Chang J; Ho AS; Sie ZL; Peng CL; Wang CL; Dev K; Chang CC
    Cancer Immunol Immunother; 2024 Jul; 73(9):175. PubMed ID: 38953994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
    Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
    Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
    Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
    Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
    PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation.
    Xiong H; Xi Y; Yuan Z; Wang B; Hu S; Fang C; Cai Y; Fu X; Li L
    Oncoimmunology; 2022; 11(1):2044103. PubMed ID: 35273829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
    Parkes EE; Walker SM; Taggart LE; McCabe N; Knight LA; Wilkinson R; McCloskey KD; Buckley NE; Savage KI; Salto-Tellez M; McQuaid S; Harte MT; Mullan PB; Harkin DP; Kennedy RD
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells.
    Kim J; Jang H; Lee GJ; Hur Y; Keum J; Jo JK; Yun SE; Park SJ; Park YJ; Choi MJ; Kim KS; Kim J
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy enhances CXCR3
    Wang CL; Ho AS; Chang CC; Sie ZL; Peng CL; Chang J; Cheng CC
    Cancer Immunol Immunother; 2023 Jun; 72(6):1865-1880. PubMed ID: 36688994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
    Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H
    Front Immunol; 2024; 15():1372215. PubMed ID: 38655266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
    Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
    Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
    [No Abstract]   [Full Text] [Related]  

  • 19. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
    Zhou F; Wang X; Liu F; Meng Q; Yu Y
    Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.